MedPharm offers services for transepithelial and topical products which includes early-phase research and in vitro testing. Credit: Akira AB November8/Shutterstock.

MedPharm has appointed Bill Humphries as its new CEO, marking a significant step in the company’s strategic growth.

The move follows the company’s merger with Great Point Partners portfolio company, Tergus Pharma, in July 2024, enhancing its clinical trial manufacturing, commercial production capabilities and scientific expertise.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With more than 36 years of experience in leadership and business transformation in the life sciences and pharmaceutical industries, Humphries is poised to lead the company into its next phase of development.

His background includes roles as CEO of Alcami, where he led operational improvements, client satisfaction and revenue growth, CEO of Isosceles Pharmaceuticals and CEO of Merz North America.

Humphries has also held significant roles at Ortho-Dermatologics, Stiefel and Allergan Pharmaceuticals.

He also served as Clearside Biomedical’s board chairman, STRATA Skin Sciences’ executive chairman, and as a board member for Aclaris Therapeutics, Alcami, PhaseBio Pharmaceuticals, Bryn Pharmaceuticals and SKNV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Humphries said: “It is a privilege to join MedPharm and the team at this important period in [its] evolution and growth aspirations.

“I am excited to be part of this team and leverage my direct experience in the topical and transdermal space to accelerate MedPharm’s growth. I believe MedPharm is well positioned to serve clients across all channels in the topical space, and we look forward to delivering incremental value for trusted existing and new clients.”

MedPharm offers a range of end-to-end contract services for transepithelial and topical products. This includes early-phase research, in vitro testing services, clinical and commercial manufacturing and formulation development.

The company is backed by investors Bourne Partners Strategic Capital, Great Point Partners and Ampersand Capital Partners.

It has facilities in both the US and the UK, including a new 97,000ft² manufacturing facility in Durham, North Carolina, US.